Biotechnology

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline

November 14, 2024 8:30 AM

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. ...

Read more

Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024 8:30 AM

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business developments. Recent Milestones & Q3 Business Highlights Merger Completion : On August 15, 2024, Silexion completed its business combination with Moringa...

Read more

Enalare Therapeutics is Granted a New Patent for ENA-001, Extending Its Exclusivity in the U.S. to 2043

November 14, 2024 8:00 AM

The New Patent Covers ENA-001 Methods of Treating Respiratory Depression Caused by Propofol, a Widely Used, Centrally Acting Anesthetic PRINCETON, NJ / ACCESSWIRE / November 14, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that the U.S. Patent and Trademark Office...

Read more

Vicore to Present at Upcoming Investor Conferences

November 14, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, November 14, 2024 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences: Stifel 2024 Healthcare Conference Location: New York, United States Presenter: Ahmed Mousa, CEO Presentation Date and...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

November 13, 2024 8:30 AM

FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024. "Over the course of the past quarter, we have continued to make progress advancing our DNase platform. Our focus is to leverage...

Read more

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

November 13, 2024 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in...

Read more

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

November 12, 2024 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the third quarter ended September 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team...

Read more

Lifeloc Reports Third Quarter 2024 Results

November 12, 2024 4:13 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2024. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.087 million in the third quarter of 2024, resulting in a quarterly net loss of $(158) thousand, or $(0.06) per diluted share. These results compare to net...

Read more

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

November 12, 2024 1:00 PM

Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q4 Investor Summit Presentation Time: 9:00am - 9:30am ET Location: https://www.webcaster4.com/Webcast/Page/3075/51643 The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market. Take...

Read more

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

November 12, 2024 9:00 AM

Data presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma (CRC) tumors FRAMINGHAM, MA / ACCESSWIRE / November 12, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on...

Read more

Inner State, Inc. Launches Research Project With The Ohio State University to Identify Psilocybin Mushroom Genetics, Novel Extracts, and Serotonin Receptor Binding Affinity Research to Discover New Bioactive Compounds

November 12, 2024 8:00 AM

COLUMBUS, OH / ACCESSWIRE / November 12, 2024 / Inner State, Inc., a women's health and wellness research and development company, and The Ohio State University announce the initiation of a research project to identify psilocybin mushroom genetics, novel extracts, and potential bioactivity. This research focuses on isolating fungi and evaluating their serotonin receptor binding affinity in an attempt to discover new medicinal natural products....

Read more

Bionoid Pharma, Inc. Signs Binding Letter of Intent to Acquire Main E-Commerce Platform of Your Supplement Supply Store Ltd.

November 12, 2024 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is excited to announce the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd. to acquire its leading e-commerce platform, EnhancedSupplements.net. This acquisition marks a pivotal step in Bionoid's strategic growth plan to accelerate its expansion into the health and wellness sector, supported by a scalable e-commerce platform that can be seamlessly enhanced with...

Read more

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

November 11, 2024 8:15 AM

Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo...

Read more

ClearPoint Neuro Reports Third Quarter 2024 Results

November 7, 2024 4:05 PM

SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024. Third Quarter Highlights Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR™ platform and...

Read more

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

November 7, 2024 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has extended its previously announced Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's program on the combination of systemic...

Read more

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 7, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on...

Read more

Bionoid Pharma, Inc. Engages Olayinka Oyebola & Co. as PCAOB External Auditor for Annual Financial Audit

November 7, 2024 7:30 AM

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is pleased to announce the formal engagement of Olayinka Oyebola & Co., a PCAOB-registered firm, as the company's external auditor. This appointment marks an important step in enhancing BINP's commitment to transparency, accountability, and adherence to regulatory standards in financial reporting. Under this agreement, Olayinka Oyebola &...

Read more

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies

November 6, 2024 8:30 AM

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss...

Read more

Adnexus Biotechnologies Inc. Announces a Merger Agreement to Acquire Sanctum Therapeutics Corporation

November 6, 2024 7:30 AM

DALLAS, TX / ACCESSWIRE / November 6, 2024 / Adnexus Biotechnologies Inc. is pleased to announce the completion of a merger agreement with Sanctum Therapeutics Corporation to acquire Sanctum Therapeutics and its core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise, including technology being developed at the Missouri Innovation Center, Columbia,...

Read more

Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024

November 6, 2024 3:00 AM

LUND, SE / ACCESSWIRE / November 06, 2024 / Alligator Bioscience (STO:ATORX) The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Confirmed ORR of 42.1%, unprecedented median DoR of 12.6 months and a median overall survival of 14.9 months strengthen the earlier reported results Near doubling of overall survival estimate at 18 months vis a vis FOLFIRINOX Second...

Read more